Q3 2023 Ascelia Pharma AB Earnings Call Transcript
Welcome, everyone, to the webcast for Ascelia Pharma's Q3 report here in 2023. The headline for this quarter is that the re-evaluation process is on track. And in this report, we'll give you an update on the business before opening up for questions.
We will be making certain forward-looking statements on this call, so please pay attention to this. Our quarterly call is structured so that we start with the Ascelia Pharma's highlighted recent key events that will be followed by a portfolio update before moving to financials. So I'm Magnus Corfitzen, CEO of Ascelia Pharma. And with me today, I have Julie Brogren, Deputy CEO; and Andreas Norlin, Chief Scientific Officer.
Ascelia Pharma is dedicated to improving the lives of people living with cancer by offering better treatment options. In particular, we focus on rare cancer conditions. Our business model is to identify, develop, and commercialize novel drugs that address unmet medical needs within orphan oncology.
We have two drugs in clinical development. Orviglance has completed
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |